Efficacy of Bromopride and Simethicone Versus Bromopride in Functional Dyspepsia
- Conditions
- Dyspepsia
- Interventions
- Drug: FDC Bromopride 10 mg and Simethicone 80 mg
- Registration Number
- NCT02604576
- Lead Sponsor
- EMS
- Brief Summary
Multi-center, randomized, superiority, double blind clinical trial to asses the efficacy of fixed-dose combination of bromopride and simethicone versus isolated bromopride on research participants diagnosed with functional dyspepsia.
- Detailed Description
Multi-center, randomized, superiority, double blind clinical trial to asses the efficacy of fixed-dose combination of bromopride and simethicone versus isolated bromopride in the relief os dyspepsia symptoms on research participants diagnosed with functional dyspepsia.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 339
- Signed Informed Consent;
- Participants aged 18- 70 years;
- Clinical diagnosis of functional dyspepsia according to Rome III criteria;
- Minimum score of 22 points in PADYQ questionnaire
- Diagnosis of gastroesophageal reflux disease, irritable bowel syndrome, inflammatory bowel disease, gallstones, strongyloidiasis, giardiasis or ascariasis, clinical disease or significant psychological;
- Positive diagnosis for Helicobacter pylori;
- Clinically significant organic diseases in the HDE (High Digestive Endoscopy) prior to randomization;
- History of esophageal surgery, gastrointestinal or other intra-abdominal surgery;
- Hypersensitivity to the components of the formulations;
- Allergy tartrazine yellow dye;
- Allergy to aspirin;
- Use of PPIs, H2 blockers, prokinetics, antibiotics, prostaglandins or bismuth salts in the last week before the screening visit;
- Use of NSAIDs or aspirin more than two days a week (except AAS <325mg / day), other drugs that induce gastrointestinal symptoms;
- Pregnant women or women without adequate contraception;
- Advance Participation in clinical trial protocols in the last twelve (12) months (CNS Resolution 251 of August 7, 1997, Part III, subsection J), unless the investigator considers that there may be direct benefit to it;
- Changes in hematological and biochemical tests: hemoglobin less than 12 g / dl, results with value 2 times the reference for AST, ALT, Gamma GT and alkaline phosphatase;
- Diagnosis of neurological or psychiatric diseases or decompensated diabetes;
- Use of drugs with anticholinergic action, narcotic analgesics, sedatives, hypnotics or tranquilizers;
- Alcoholism or sporadic use of alcohol and illicit drug use.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Group 2 Bromopride 10 mg Bromopride 10 mg (Digesan ® - Sanofi Aventis) Group 1 FDC Bromopride 10 mg and Simethicone 80 mg FDC Bromopride 10 mg and Simethicone 80 mg
- Primary Outcome Measures
Name Time Method Symptoms assessed by proportion of participants who have reduction equal to or greater than 50% in symptoms through questionnaire PADYQ 4 weeks
- Secondary Outcome Measures
Name Time Method Adverse events 4 weeks Safety assessment will be performed by evaluating the incidence of adverse events in each group as well as the relationship of these events to the drug used, the amount and severity of reported events.
Trial Locations
- Locations (10)
Centro de Medicina Reprodutiva Carlos Isaia Filho Ltda
🇧🇷Porto Alegre, Rio Grande Do Sul, Brazil
Allergisa
🇧🇷Campinas, São Paulo, Brazil
Hospital de Clínicas de Porto Alegre
🇧🇷Porto Alegre, Rio Grande Do Sul, Brazil
Instituto de Pesquisa Clinica de Campinas
🇧🇷Campinas, SP, Brazil
Loema
🇧🇷Campinas, SP, Brazil
UNIFAG
🇧🇷Bragança Paulista, SP, Brazil
Hospital Ernesto Dornelles
🇧🇷Porto Alegre, RS, Brazil
Faculdade de Medicina do ABC
🇧🇷Santo André, SP, Brazil
Centro de Estudos Clínicos do Interior Paulista
🇧🇷Jau, SP, Brazil
AFIP
🇧🇷São Paulo, Sâo Paulo, Brazil